The Pathways to Health Careers Act establishes a federal grant program effective October 1, 2026, to train low-income individuals for careers in health professions such as nursing, emergency medical services, and allied health fields. The legislation allocates $435 million annually from fiscal years 2027 through 2031 to fund these initiatives, with specific requirements ensuring that at least two grants are awarded in each state and the District of Columbia, along with dedicated funding for tribal entities and U.S. territories. Key provisions mandate that grant recipients provide comprehensive support services, including adult basic education, childcare, transportation assistance, and cash stipends, while also requiring rigorous evaluations of demonstration projects focused on individuals with criminal records and maternal health career pathways.
The Protect American Values Act of 2026 prohibits the use of federal funds to implement or enforce a specific Department of Homeland Security rule regarding the "Public Charge" ground of inadmissibility. This legislation directly affects immigrants and their families by preventing the government from using financial resources to carry out policies that could restrict access to essential services like food, medical care, and housing. The bill includes a statement of congressional intent arguing that the targeted rule would harm community health, increase poverty, and circumvent established immigration laws. By blocking funding for this specific regulatory action, the act aims to maintain current eligibility standards for public assistance without altering the underlying statutory framework.
The Health Care Fraud Prevention and Enforcement Act mandates increased funding for federal agencies, including the Department of Justice, the Department of Health and Human Services, and the Federal Bureau of Investigation, to combat health care fraud and abuse starting in fiscal year 2027. The bill expands the investigative authority of the HHS Office of Inspector General to cover programs established under the Affordable Care Act and includes the State Children's Health Insurance Program in Medicare-Medicaid data matching efforts. Additionally, it requires the Government Accountability Office to conduct a study on the program's performance and effectiveness, with results due to Congress within 16 months of enactment.
The PREFERRED Screening Act directs the Secretary of Health and Human Services to implement a seven-year payment model that reimburses healthcare providers for conducting comprehensive breast cancer risk assessments and creating personalized screening plans for Medicare beneficiaries aged 40 to 75. These assessments combine genetic testing, family history, and lifestyle factors to categorize patients by risk level, which then guides specific recommendations for screening frequency, imaging types, and preventive medications. The model prioritizes participation from providers in rural areas, medically underserved communities, and states with high breast cancer mortality rates, while allowing services to be delivered through both in-person visits and remote methods such as mailed genetic testing kits. Throughout the program, the government will evaluate whether this approach changes patient behavior, affects healthcare costs, and improves early detection of breast cancer before deciding if the model should be expanded or made permanent.
The Colorectal Cancer Early Detection Act authorizes the Centers for Disease Control and Prevention to provide competitive five-year grants to states, the District of Columbia, and U.S. territories to improve awareness and early detection of colorectal cancer in individuals under age 45. These funds are intended to support outreach and education campaigns that target young people with specific risk factors, such as a family history of the disease or inflammatory bowel conditions, as well as underserved populations including rural residents and certain racial and ethnic groups. Grant recipients must partner with healthcare providers and community organizations to facilitate diagnostic testing, offer patient navigation services, and train medical professionals on recognizing symptoms in younger patients. States receiving these grants are required to submit reports detailing their use of funds and the effectiveness of their implemented programs after five years.
The Mobile Medical Unit Rural Expansion Act of 2026 directs the Department of Veterans Affairs to designate a specific office to oversee its mobile medical unit program and conduct a nationwide inventory of these vehicles. The bill requires the Secretary of Veterans Affairs to assess the feasibility of mandating annual deployments of these units to rural or underserved areas to improve healthcare access for veterans. Additionally, it mandates a comprehensive report to Congress identifying gaps in current capabilities, staffing, and funding barriers, as well as strategies for better engaging local veterans service organizations to optimize deployment locations.
The Stroke Act directs the Department of Health and Human Services to conduct research on stroke care delivery and award grants to improve national stroke data collection and quality. The legislation authorizes funding for a national stroke registry that gathers standardized information from various types of hospitals to support quality improvement and benchmarking. Additionally, it provides grants for training emergency medical personnel, expanding telestroke services in underserved areas, and coordinating post-stroke rehabilitation. Finally, the bill funds a national public education campaign aimed at promoting stroke prevention and encouraging individuals to seek immediate treatment for symptoms.
The Pay PCPs Act of 2026 authorizes the Secretary of Health and Human Services to implement a hybrid payment model for Medicare primary care providers, combining predictable monthly payments with traditional fee-for-service reimbursements. This new structure aims to fund activities that are currently difficult to bill individually, such as patient communications and team-based care coordination, while allowing providers to opt into the program voluntarily. Additionally, the bill reduces beneficiary out-of-pocket costs by 50% for covered primary care services when patients designate a specific provider as their usual source of care. To support these changes, the legislation appropriates $10 billion over five years and establishes a temporary technical advisory committee to review and improve how Medicare values physician services.
The Momnibus Act is a comprehensive legislative package designed to address maternal health disparities by expanding access to care, improving data collection, and funding community-based interventions for pregnant and postpartum individuals. Key provisions include extending WIC nutrition benefits for new mothers from six months to two years, establishing a federal task force to coordinate efforts across government agencies, and creating grant programs to support social determinants of health such as housing, transportation, and mental health services. The bill also mandates respectful maternity care training for hospital staff, requires states to restrict the shackling of pregnant individuals in prison to maintain federal funding eligibility, and authorizes significant research funding through the National Institutes of Health to study maternal mortality causes and climate change impacts on pregnancy outcomes.
The Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026 requires federal agencies to include reasonable pricing clauses in all research grants and contracts involving biomedical products. Under this provision, U.S. residents cannot be charged more than the median price found in Canada and six other high-income OECD countries for any drug, device, or therapy developed with federal support. The Secretary of Health and Human Services is authorized to establish additional regulations, such as mechanisms to lower prices when revenues exceed targets or costs per health benefit are too high, while retaining the ability to waive these obligations if doing so serves the public interest. To ensure accountability, manufacturers must report clinical trial costs, government subsidies, and annual revenues by county, with all data made publicly available.
